IL2 and melanoma: One series reported that metastasectomy did not convincingly achieve prolonged PFS for patients with progressive melanoma who responded to high-dose IL-2.12 Conversely, another study noted that patients with metastatic melanoma made free of disease by thoracic resection had a 5-year actuarial survival rate of 76 %; the majority of these patients had been treated with IL-2, vaccine, or interferon.13 To our knowledge, the reported experience with metastasectomy for metastatic melanoma following checkpoint inhibition is limited to a single report.